Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced long-term efficacy and safety data from a two-year long open-label extension (OLE) study of investigational plozasiran supporting its ...
There has been an increase in heart attacks and heart-related events. While most reports suggest that such cardiac events are sudden, this is not entirely true. A majority of people only focus on ...
Brigham and Women's Hospital investigators link very high lipoprotein(a) with a higher 30-year risk of major cardiovascular events in initially healthy women. Elevated plasma lipoprotein(a) is a ...
Good afternoon, and welcome to the Arrowhead Pharmaceuticals REDEMPLO FDA Approval Conference Call. [Operator Instructions] As a reminder, this call is being recorded, and a replay will be made ...
CNRS, Inserm, L’Institut du Thorax, Nantes Université, France (W.D., A.R., T.S., C.L.M., B.C.). INRAE, UR1268 BIA, Nantes, France (W.D.). CNRS, Inserm, L ...
Lp(a) AW(a)RE TM Initiative Addresses Key Unmet Need for Education and Screening Among Primary Care Clinicians, Healthcare Insurance Providers and Policy Makers Eli Lilly and Company is the initial ...
NEW YORK – Ionis Pharmaceuticals and Sobi on Friday said the European Union has approved its antisense oligonucleotide therapy Tryngolza (olezarsen) as an adjunct to diet for the treatment of patients ...
Atherosclerotic cardiovascular disease (ASCVD) pathogenesis is fundamentally driven by dyslipidemia, characterized by lipid metabolism disorders that facilitate cholesterol deposition within damaged ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results